论文部分内容阅读
目的观察自体树突状细胞(DC)疫苗联合细胞因子诱导的杀伤细胞(CIK细胞)治疗胆系肿瘤的临床疗效。方法采集患者外周血单个核细胞,采用多种肿瘤抗原刺激后进行扩增和培养,收获成熟DC制成疫苗进行皮内注射,同时联合自体CIK细胞静脉回输,观察85例胆系肿瘤患者治疗前后的临床疗效、免疫功能、不良反应及生存时间。结果 85例胆系肿瘤患者经自体DC-CIK细胞治疗后,临床症状较前明显改善(P<0.05);临床疗效显著,完全缓解2例(2.3%)、部分缓解14例(16.5%)、疾病稳定54例(63.5%)及疾病进展15例(17.6%);免疫功能提高,治疗后淋巴细胞亚群中CD3+、CD3+CD4+、CD3+CD8+、CD3+CD56+及CD4+/CD8+比值升高,而调节性T细胞降低(P<0.05)。至随访结束,58例患者死亡,2例失访,25例存活,中位生存期为16.5个月(95%CI:12.1~20.9个月)。结论自体DC-CIK细胞治疗是胆系肿瘤患者一种安全有效的治疗方法,不良反应少,但相关结论仍有待进一步大样本随机对照研究证实。
Objective To observe the clinical efficacy of autologous dendritic cells (DC) vaccine combined with cytokine-induced killer cells (CIK cells) in the treatment of gallbladder tumors. Methods Peripheral blood mononuclear cells (PBMCs) were collected from patients and stimulated with various tumor antigens to amplify and culture. The mature DCs were harvested and injected intradermally. Combined with intravenous infusion of autologous CIK cells, 85 patients with cholangiocarcinoma were treated Before and after the clinical efficacy, immune function, adverse reactions and survival time. Results The clinical symptoms of 85 cases of cholangiocarcinoma patients were significantly improved after treatment with autologous DC-CIK cells (P <0.05). The clinical effect was significant, complete remission in 2 cases (2.3%) and partial remission in 14 cases (16.5% 54 cases (63.5%) had stable disease and 15 cases (17.6%) had disease progression. The immune function was improved and the ratio of CD3 +, CD3 + CD4 +, CD3 + CD8 +, CD3 + CD56 + and CD4 + / CD8 + in lymphocyte subsets increased after treatment, While regulatory T cells decreased (P <0.05). At the end of the follow-up period, 58 patients died, two lost their patients and 25 survived. The median survival time was 16.5 months (95% CI: 12.1-20.9 months). Conclusions Autologous DC-CIK cell therapy is a safe and effective treatment for patients with cholangiocarcinoma with fewer adverse reactions, but the relevant conclusions still need further large randomized controlled studies confirmed.